Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKinsey
Express Scripts
Medtronic
Moodys

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,978,945

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,978,945 protect, and when does it expire?

Patent 6,978,945 protects EVAMIST and is included in one NDA.

This patent has seventeen patent family members in ten countries.

Summary for Patent: 6,978,945
Title: Dispensing device
Abstract:Hand-held dispensing devices for dispensing and applying a substance to the skin of a host are described. The devices include a hollow body, a capsule mounted within the hollow body for containing the substance, a nozzle mounted within the hollow body communicating with the substance in the capsule, an actuator to cause metered quantities of the substance to be dispensed from the capsule through the nozzle, a shroud defining an exit space for receiving the substance emerging from the nozzle, and a cap detachably mounted on the shroud to selectively open and close the nozzle and thereby control escape of the substance from the capsule.
Inventor(s): Wong; Kon Euan (Glen Waverly, AU), Bayly; Mark Simon (Eltham North, AU)
Assignee: Acrux DDS Pty Ltd (AU)
Application Number:10/442,323
Patent Claim Types:
see list of patent claims
Dosage form; Device; Composition; Formulation;

Drugs Protected by US Patent 6,978,945

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,978,945

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPR1845Dec 01, 2000

International Family Members for US Patent 6,978,945

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002220352   Start Trial
Australia 2005234689   Start Trial
Australia 2035202   Start Trial
Canada 2436882   Start Trial
European Patent Office 1345549   Start Trial
Hungary 0302569   Start Trial
Japan 2004513755   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
AstraZeneca
Colorcon
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.